A DDI Study of FDL169 and FDL176 in Healthy Subjects
NCT03756922 · Status: SUSPENDED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 78
Last updated 2020-02-05
Summary
A DDI study to assess the safety, tolerability and pharmacokinetics of both; doses of FDL176 with and without co-administration of FDL169 and doses of FDL169 with and without co-administration of FDL176.
Conditions
Interventions
- DRUG
-
FDL169
CFTR corrector
- DRUG
-
FDL176
CFTR potentiator
Sponsors & Collaborators
-
Flatley Discovery Lab LLC
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2018-11-27
- Primary Completion
- 2020-02-29
- Completion
- 2020-02-29
Countries
- United Kingdom
Study Locations
More Related Trials
-
FTIH - Single and Repeat Oral Doses of FDL169 in Healthy Volunteers
NCT02359357 ·Status: COMPLETED ·Phase: PHASE1
-
An Phase 1 Study to Evaluate the Pharmacokinetic (PK) Profile of FDL169 New Formulations in Healthy Subjects
NCT03424252 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Safety, Tolerability and PK Profile of FDL176 in Healthy and CF Participants
NCT03173573 ·Status: COMPLETED ·Phase: PHASE1
-
Observational Trial of the Longitudinal Effects of CFTR Modulator Drugs
NCT04353752 ·Status: COMPLETED
-
Safety Study of Fenretinide in Adult Patients With Cystic Fibrosis
NCT02141958 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis
NCT03119649 ·Status: COMPLETED ·Phase: PHASE2
-
Assessment of CFTR-Modulator Treatment in Cystic Fibrosis Lung Disease Using Novel Structural and Functional MRI
NCT04391322 ·Status: ACTIVE_NOT_RECRUITING
-
Phenylbutyrate/Genistein Duotherapy in Delta F508-Homozygous(for Cystic Fibrosis)
NCT00016744 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis.
NCT03540524 ·Status: COMPLETED ·Phase: PHASE1
-
Molecular Phenotypes for Cystic Fibrosis Lung Disease
NCT01116414 ·Status: COMPLETED
-
A Study to Confirm the Long-term Safety and Effectiveness of Kalydeco in Patients With Cystic Fibrosis Who Have an R117H-CFTR Mutation, Including Pediatric Patients
NCT02722057 ·Status: COMPLETED
-
Genetic Modifiers of Cystic Fibrosis Related Diabetes
NCT01113216 ·Status: ENROLLING_BY_INVITATION
-
Combined Effect of CFTR Protein Modulator Drugs and Exercise in Cystic Fibrosis
NCT04415268 ·Status: WITHDRAWN ·Phase: NA
-
Gene Modifiers of Cystic Fibrosis Lung Disease
NCT00037765 ·Status: ACTIVE_NOT_RECRUITING
-
Glucose Metabolism in Cystic Fibrosis Related Diabetes (CFRD)
NCT07102043 ·Status: NOT_YET_RECRUITING
-
A Safety and Tolerability Study OF PUR118 In Subjects With Cystic Fibrosis
NCT01543191 ·Status: COMPLETED ·Phase: PHASE1
-
Genetic Modifiers of Cystic Fibrosis: Sibling Study
NCT00037778 ·Status: COMPLETED
-
Study Assessing PTI-428 Safety, Tolerability, Pharmacokinetics and Effect in Subjects With Cystic Fibrosis
NCT03591094 ·Status: COMPLETED ·Phase: PHASE2
-
Diagnosis and Treatment of Patients With Cystic Fibrosis
NCT00001223 ·Status: TERMINATED
-
Statins To Treat Adult Cystic Fibrosis
NCT01092572 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
A Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis
NCT03045523 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Cystic Fibrosis
NCT00757848 ·Status: COMPLETED ·Phase: PHASE2
-
Study of GLPG1837 in Subjects With Cystic Fibrosis (S1251N Mutation)
NCT02690519 ·Status: COMPLETED ·Phase: PHASE2
-
Testing Drug Efficacy in Cystic Fibrosis Through N-of-1 Trials
NCT04580368 ·Status: RECRUITING ·Phase: NA
-
Study to Assess Efficacy of AZD1236 in Patients With Cystic Fibrosis
NCT00812045 ·Status: WITHDRAWN ·Phase: PHASE2